Document:

Amendment to Employment Agreement, Craig Philips, dated December 31, 2008

 Exhibit 10.10 
 December 31, 2008 
 Mr. Craig Philips 
 __________________ 
 __________________ 
 Dear Craig: 
 You (“Employee”) and Cell Therapeutics, Inc., a Washington corporation (“CTI” or
the “Company”) previously entered into an employment agreement dated April 23, 2008 (the “Employment Agreement”). This letter agreement amends the Employment Agreement to the extent necessary to provide that
the termination benefits set forth therein will comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. Except as otherwise amended pursuant to this letter agreement, the Employment Agreement remains in
full force and effect. Any terms used but not otherwise defined herein shall have the meaning set forth in the Employment Agreement. 
 Section 8 of the Employment Agreement is hereby amended and restated in its entirety as follows: 
 “8. Termination Benefits. 
 (a) In the event Employee’s employment is terminated without
Cause by the Company or by the Employee for Good Cause (as defined below) and provided that such termination constitutes a “separation from service” as defined in Treasury Regulation Section 1.409A-1(h) (“Separation”)
and that Employee satisfies the Conditions by the Deadline (each as defined below), Employee will be entitled to (i) an amount equivalent to eighteen (18) months (the “Severance Period”) of Employee’s base salary
(which severance payments shall not be at less than his initial base salary rate set forth in paragraph 2 above), payable pursuant to Company’s normal payroll procedure during the Severance Period, which shall be paid beginning on the
Company’s first normal payroll date that occurs on or after the Deadline, and (ii) direct payment by the Company to the COBRA administrator for continuing Employee’s medical, dental and vision coverage for himself and his dependents
under the Consolidation Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) for the Severance Period, provided Employee makes a timely election for such continued coverage, and (iii) accelerated vesting of any
unvested equity, including stock options and restricted stock, that has vesting dates within one year from the date of Employee’s termination, (clauses (i) and (ii) and (iii), collectively, the “Severance Pay”). The
Severance Pay shall be conditioned upon (A) timely execution by Employee of a general release of claims (the “Release”) in a form reasonably acceptable to the Company and the non-revocation and effectiveness of such Release,
(B) voluntary resignation from all of Employee’s positions with the Company, and (C) continued compliance with the provisions of this Agreement, including the covenants contained in Sections 4, 5 and 6 of this Agreement (collectively,
the “Conditions”), in each case within sixty (60) days following Employee’s Separation (the “Deadline”). 

 (b) In the event Employee is terminated without Cause or Employee voluntarily terminates
his employment in connection with or within twelve (12) months following a Change of Control of the Company and provided that such termination constitutes a Separation and Employee satisfies the Conditions by the Deadline, he will be entitled
to the Severance Pay described in and subject to the provisions of paragraph 8(a) above. Additionally, and notwithstanding Section 8(a)(iii), he will be entitled to all equity vesting acceleration as set forth in the Consulting Letter
Agreement referenced in the recitals to this Agreement. 
 (c) In the event Employee’s employment is terminated by the
Company at any time with Cause, he will not be entitled to Severance Pay, pay in lieu of notice or any other such compensation (other than earned but unpaid salary and benefits, including any accrued but unpaid vacation pay or paid time off
amounts). 
 (d) In the event Employee’s employment is terminated by the Company because of Disability, in addition to
any short-term or long-term disability benefits he may be entitled to under any Company group disability plans, he will be paid for all earned but unpaid salary and benefits, including any accrued but unpaid vacation pay or paid time off amounts,
and, provided such termination constitutes a Separation and Employee satisfies the Conditions by the Deadline, Employee shall be entitled to a pro rata share of his target bonus for the year in which his termination occurs, to be paid to Employee in
the year following the year of Employee’s Separation and, to the extent made during such year, on the date such bonus would have been paid had Employee remained employed by the Company and in accordance with the Company’s normal payroll
procedures. In addition, the Company will directly pay the COBRA administrator premiums for Employee’s COBRA coverage for the period of time Employee is eligible for COBRA, provided Employee timely elects such coverage. 
 (e) For purposes of Section 409A of the Internal Revenue Code of 1986, as amended, each payment that is paid pursuant to
Section 8(a)(i) above, whether through Sections 8(a) or 8(b), and any pro-rata target bonus that Employee would otherwise be entitled to pursuant to Section 8(d) above is hereby designated as a separate payment. Notwithstanding anything
stated herein, if the Company (for this purpose, “employer” as defined in Treasury Regulation Section 1.409A-1(h)(3)) is publicly traded on an established securities market or otherwise at the time of Employee’s Separation and,
at the time of Employee’s Separation he is a “specified employee,” as defined in Treasury Regulation Section 1.409A-1(i), then any severance that Employee would otherwise be entitled to pursuant to Section 8(a)(i) above,
whether through Sections 8(a) or 8(b), and any pro-rata target bonus that Employee would 

  

 - 2 - 

 
otherwise be entitled to pursuant to Section 8(d) above during the six (6) month period following his Separation, shall not be paid during such six
(6) month period and shall instead be paid on the first business day following the expiration of such six (6) month period or, if earlier, the date of Employee’s death, and any remaining payments shall continue to be paid in
accordance with the first paragraph of this Section 8.”  
 This letter agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. To indicate your acceptance of this letter agreement, please sign and date this letter in the space provided below
on or before December 31, 2008 and return it to me. 
 IN WITNESS WHEREOF, the parties have executed this letter agreement on the date(s)
set forth below. 
  

									
	 “COMPANY”
 Cell
Therapeutics, Inc.
	 	 	 	 “EMPLOYEE”
 Craig
Philips

				
	By:	 	/s/ James Bianco, M.D.	 		 	/s/ Craig Philips
		 	 James Bianco, M.D.
 Chief Employee
Officer
	 		 	Craig Philips

									
					
	Dated:	 	December 31, 2008	 		 	Dated:	 	December 31, 2008

  

 - 3 -Director Compensation Policy

 Exhibit 10.19 
 CELL THERAPEUTICS, INC. 
 REVISED DIRECTOR COMPENSATION POLICY 
 Effective January 1, 2009 
 Non-employee directors of Cell Therapeutics, Inc., a Washington corporation (the “Company”) shall be entitled to the compensation set forth below for their service as a member of the Board of Directors (the “Board”) of
the Company. This policy supersedes all prior policies or provisions of any equity plans concerning compensation of the Company’s non-employee directors, except that any prior equity awards previously earned by a director, but which have not
yet been granted, remain valid. 
 Cash Compensation 
 Annual Retainer for Board Service 
 Effective January 1, 2009, each non-employee director
shall be entitled to an annual cash retainer in the amount of $25,000 (the “Annual Retainer”). The Company shall pay the Annual Retainer on a semi-annual basis paid, with half of the Annual Retainer to paid on each of the first business
day of January and July. 
 Annual Retainer for Chairman of the Board Service 
 Effective January 1, 2009, a non-employee director who serves as the Chair of the Board shall be entitled to an annual cash retainer in the amount of
$52,500 (the “Chair of the Board Retainer”). The Company shall pay the Chair of the Board Retainer on a semi-annual basis, with half of the Annual Retainer to paid on each of the first business day of January and July. 
 Board Committee Chair Retainer 
 Effective January 1, 2009, a non-employee director who serves as the Chair of the Audit, Compensation or Nominating and Corporate Governance committee of the Board shall be entitled to an annual cash retainer in the amount of $10,000
(the “Chair Retainer”). The Company shall pay the Chair Retainer on a semi-annual basis, with half of the Annual Retainer to paid on each of the first business day of January and July. 
 Board Meeting Attendance Fee 
 Commencing April 1, 2007, a non-employee director who attends a Board meeting, whether in person or telephonic and regardless of length, will be entitled to a fee in the amount of $2,000 (“Board Meeting Fee”) for each
meeting. The Company shall pay the Board Meeting Fee on a quarterly basis in arrears. 

 Board Committee Meeting Attendance Fee 
 Commencing April 1, 2007, a non-employee director who attends a committee meeting, whether in person or telephonic and regardless of length or
whether a meeting is scheduled on the same day as a Board meeting, will be entitled to a fee in the amount of $1,000 (“Committee Meeting Fee”) for each meeting. The Company shall pay the Committee Meeting Fee on an annual basis paid on a
quarterly basis in arrears. 
 Equity Compensation 
 Initial Equity Award for New Directors 
 For new non-employee directors appointed or elected
after January 1, 2007, on the date a new director becomes a member of the Board, each non-employee director shall automatically receive a grant as follows: a restricted stock award of 3,000 shares of Company’s common stock and an option to
purchase 9,000 shares of the Company’s common stock (an “Initial Award”), with such option to have an exercise price equal to the closing price of the Company’s common stock on the date of grant. The Initial Award is subject to
vesting over a period of three years in equal annual installments commencing on the date of grant, subject to the non-employee director’s continued service to the Company through the vesting dates. An employee director who ceases to be an
employee, but who remains a director, will not receive an Initial Award. 
 Annual Equity Award for Continuing Board Members 

 Commencing with the 2008 Annual Meeting of Stockholders, each continuing non-employee director shall automatically receive an annual grant
as follows: a restricted stock award of 9,000 shares of the Company’s common stock and an option to purchase 36,000 shares of the Company’s common stock (an “Annual Award”), with such option to have an exercise price equal to the
closing price of the Company’s common stock on the date of grant. The Annual Award for continuing Board members shall vest in full on the earlier of (i) the one year anniversary of the date of grant and (ii) the date immediately
preceding the date of the Annual Meeting of the Company’s stockholders for the year following the year of grant for the award, subject to the non-employee director’s continued service to the Company through the vesting date. 
 Provisions Applicable to All Non-Employee Director Equity Compensation Grants 
 All grants shall be subject to the terms and conditions of the Company’s 2007 Equity Incentive Plan, or any other equity compensation plan approved
by the Company’s shareholders, and the terms of the restricted stock agreement or option agreement issued thereunder. 
 Any unvested
shares underlying non-employee director option grants or restricted stock awards shall become fully vested in the event of a change in control with respect to the Company while such non-employee director is a member of the Board. 
  

 2 

 Expense Reimbursement 
 All non-employee directors shall be entitled to reimbursement from the Company for their reasonable travel (including airfare and ground transportation), lodging and meal expenses incident to meetings of the Board or
committees thereof or in connection with other Board related business. The Company shall also reimburse directors for attendance at director continuing education programs that are relevant to their service on the Board and which attendance is
pre-approved by the Chair of the Nominating and Corporate Governance Committee or Chair of the Board. The Company shall make reimbursement to a non-employee director within a reasonable amount of time following submission by the non-employee
director of reasonable written substantiation for the expenses. 
  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]